Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.
April 11th, 2016 – (NASDAQ: FNJN) called at $1.07/share hit $1.76/share in 3 days for 64% gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
–Report on:(Nasdaq: AMRS )
What: Shares of Amyris Inc. (NASDAQ:AMRS) jumped as much as 34% in early trading today after announcing a major supply agreement. But by midday on Wall Street, shares had settled to a more muted 7% gain.
So what: Amyris said it has signed a five-year Biofene supply agreement with an unnamed “global nutraceuticals company.” This replaces a one-year purchase agreement announced earlier this year and is expected to add $9 million to 2016 revenue with minimum purchase commitments in subsequent years. In total, the agreement is expected to be worth more than $100 million in revenue.
Now what: These kind of agreements should be what grows Amyris’ business long term and that’s what investors were buying into this morning. But the company has also made promising statements about growth in the past that haven’t come true.
At the end of the day, I think investors should view this announcement as an incremental positive for Amyris. But until the company proves that these contracts will drive real revenue and get to cash flow breakeven, I would be leery about betting too big on a recovery in the stock. The growth story in industrial biosciences is phenomenal, but until that story starts becoming a reality, it’s still a high-risk investment.
Source: The Motley Fool
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.
Broad Street Alerts was previously compensated eighteen thousand five hundred dollars by star media llc for the mention of FNJN however, that contract has expired.